A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

NCT05108766 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Tildrakizumab 100 mg
DRUG: Placebo

Sponsor

Shenzhen Kangzhe Pharmaceutical Co., Ltd.